Trials / Terminated
TerminatedNCT02056938
ATG Versus Basiliximab in Kidney Transplant Displaying Low Immunological Risk But High Susceptibility to DGF
Prospective Multicentric, Randomized, Open-labeled, in Parallel Groups, Study to Assess the Benefit/Risk of an Induction Treatment With Anti-Thymocyte Globulins (ATG) Versus Basiliximab in Kidney Transplant Patients Displaying Low Immunological Risk But High Susceptibility to Delayed Graft Function.
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Nantes University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the following randomized open label trial is to demonstrate how low immunological risk patients (no anti HLA immunization and first kidney transplantation) but diagnosed at high-risk of delayed graft function (assessed by DGFS score) could benefit from induction with ATG for preventing delayed graft function compared to Basiliximab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anti-Thymocyte Globulins treatment | |
| DRUG | Basiliximab treatment |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2017-02-01
- Completion
- 2017-02-01
- First posted
- 2014-02-06
- Last updated
- 2017-11-21
Locations
4 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02056938. Inclusion in this directory is not an endorsement.